… Despite the encouraging preclinical and clinical data supporting the rationale of combining
erlotinib with sirolimus for recurrent GBM, results of the current study were disappointing. …

… sirolimus was to assess the safety and maximum tolerated dose (MTD) of vandetanib and
sirolimus in patients with recurrent GBM. … the proportion of recurrent GBM patients treated at the …

… of sirolimus for patients on EIAEDs. DLTs included mucositis, diarrhea, rash, thrombocytopenia,
and hypertriglyceridemia. Gefitinib exposure was not affected by sirolimus … plus sirolimus …

Purpose Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though
the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. …

… in recurrent high-grade glioma. Phosphatase and tensin homolog (PTEN) mutation in
glioblastoma multiforme (GBM… ), and the mammalian target of rapamycin (mTOR) and is …

… of mTOR, such as rapamycin (sirolimus), RAD-001 (everolimus) and CCI-779 (temsirolimus).
Two recently completed trials on temsirolimus in patients with recurrent GBM report a PFS-…

… We reviewed the literature on clinical trials for recurrent glioblastoma available in
PubMed and American Society of Clinical Oncology (ASCO) abstracts until June 2015. …

… sirolimus can lead to tumor response [18]. However, a subsequent phase II study of erlotinib
and sirolimus that … with recurrent GBM, but no response was seen with this combination [19]. …

… Sirolimus and … sirolimus in recurrent malignant glioma demonstrated acceptable toxicity,
26 and a pilot study of gefitinib or erlotinib and sirolimus in heavily pretreated recurrent GBM …

… therapy for recurrent glioblastoma, a Phase I trial combining sirolimus, an mTOR inhibitor, …
A retrospective study assessing response of gefitinib or erlotinib plus sirolimus showed better …